Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nat Rev Immunol. 2011 May;11(5):355-63. doi: 10.1038/nri2972. Epub 2011 Apr 15.

Overcoming hurdles in developing successful drugs targeting chemokine receptors.

Author information

  • 1ChemoCentryx, Inc., 850 Maude Avenue, Mountain View, California 94043, USA. tschall@chemocentryx.com

Abstract

Chemokines and their receptors are central to the inflammatory process and are attractive therapeutic targets. Drugs that inhibit chemokine receptors are approved for the treatment of HIV infection and for stem cell mobilization, but none have been approved yet for the treatment of inflammatory and/or autoimmune diseases. We analyse the challenges of developing chemokine receptor antagonists, and propose that inappropriate target selection and ineffective dosing, not the 'redundancy' of the chemokine system, are the main barriers to their use as anti-inflammatory therapies. We highlight evidence suggesting that chemokine receptor inhibition will prove to be an effective therapy in inflammatory diseases.

PMID:
21494268
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk